Drugs / SHR0410
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04317209 | May → Dec 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04099927 | Jul 2019 → Apr 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03857568 | Apr → Nov 2019 | — | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03493191 | Apr → Jun 2018 | — | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05394402 | Aug 2022 → May 2023 | — | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT05470049 | Aug → Nov 2022 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05459220 | Jul 2022 → Feb 2023 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04852003 | May → Jun 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR0410 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04099927 ↗ |
| Action | Activate | “KOR agonist” NCT04099927 ↗ |
| Route | Intravenous | “administered as a 15 min constant dose IV infusion” NCT03493191 ↗ |